A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

PHASE3UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Raynaud's DiseaseRaynaud's Disease Secondary to SclerodermaRaynaud's Disease Secondary to Other Autoimmune Disease
Interventions
DRUG

Nitroglycerin

Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

DRUG

Topical AmphiMatrix

Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

Trial Locations (17)

11794

SUNY Stony Brook, Stony Brook

12206

The Center for Rheumatology, Albany

20007

Georgetown University, Washington D.C.

21224

Johns Hopkins University, Baltimore

28401

Carolina Arthritis, Wilmington

29425

Medical University of South Carolina, Charleston

43614

University of Toledo, Toledo

49546

Arthritis Education and Treatment Center, PLLC, Grand Rapids

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

77030

University of Texas at Houston, Houston

80045

University of Colorado Health Sciences Center, Denver

94305

Stanford University, Stanford

06030

University of Connecticut, Farmington

02118

Boston University, Boston

08093

University of Medicine and Dentistry of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

MediQuest Therapeutics

INDUSTRY